MTH1 is highly upregulated in tumor biopsies from patients with diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma, hence confirming a rationale for targeting MTH1. The gene discussed is NUDT1; the disease is diffuse large B-cell lymphoma.